NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Granted $1M by the Alzheimer’s Association to Advance Development of XPro1595
INmune Bio (NASDAQ: INMB) this morning announced that the company has been awarded a grant to receive $1,000,000 from the Alzheimer's Association to advance XPro1595 under the Part the Cloud to RESCUE grant. XPro1595 is a novel therapy targeting neuroinflammation as a cause of Alzheimer’s disease. The award will be paid to the company in traches during the phase 1 clinical trial. “We are honored to receive this grant from the Alzheimer’s Association,” RJ Tesi, M.D., CEO of INmune Bio stated in the news release. “The Alzheimer’s Association has shown the vision and leadership to support the quest for effective…